P-gp 及对抗 P-gp 介导多药耐药的研究现状

摘要/Abstract

摘要： P-糖蛋白在多药耐药中起着重要的作用。本文就 P-gp 的蛋白结构、作用机制及其与多药耐药的关系以及对抗 P-gp 介导的 MDR 的现状做了简要介绍。总之,一方面要继续开发高效的 P-gp 抑制剂 , 同时 ,又要考虑过度抑制 P-gp 可能会带来不良影响;在抑制 P-gp 的同时 ,还要兼顾对其它耐药机制的抑制,只有这样,才能在临床上充分解决多药耐药的问题。

关键词: P-糖蛋白, 多药耐药, 抑制剂 , 基因表达

Abstract: P-glycoprotein (P-gp)plays an important role in multidrug resistance (MDR).This article was fo- cused on the protein structure and the mechanism of P- gp , and especially on the current status in anti-P-gp drug research and discovery .The action of P-gp in MDR was also reviewed .Moreover , the potential adverse reaction of P-gp inhibitors were emphasized since P-gp was involved in the normal function of a lot of organs .

Key words: p-glycoprotein ;multidrug resistance, inhibitors ;gene expression

中图分类号:

R979 .1

马秉亮, 吴玉林, 刘国卿. P-gp 及对抗 P-gp 介导多药耐药的研究现状[J]. 中国临床药理学与治疗学, 2006, 11(1): 14-21.

MA Bing-liang , WU Yu-lin , LIU Guo-qing. Progress in anti-multidrug resistance mediated by p-glycoprotein[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(1): 14-21.

参考文献

1 Murren JR.Modulating multidrug resistance-can we target this therapy[ J] ? Clin Cancer Res, 2002; 8 : 633-5
2 Ambudkar SV, Dey S , Hrycyna CA , Ramachandra M , Pastan I, Gottesman MM .Biochemical , cellular, and pharmacological as- pects of the multidrug transporter[ J] . Annu Rev Pharmacol Toxi- col, 1999; 39 : 361-98
3 Zhang JT. The multi-structural feature of the multidrug resistance gene product P-glycoprotein:implications for its mechanism of action (hypothesis) [ J] .Mol Membr Biol, 2001, 18 : 145-52
4 Lin JH , Yamazaki M.Role of P-glycoprotein in pharmacokinetics -clinical implications[ J] . Clin Pharmacokinet, 2003 ; 42: 59-98
5 Loo TW, Bartlett MC , Clarke DM . Substrate-induced conforma- tional changesin the transmembrane segments of human P-glyco- protein.Direct evidence for the substrate-induced fit mechanism for drug binding[ J] . J Biol Chem, 2003; 278: 13603 -6
6 Loo TW, Clarke DM.Determining the dimensions of the drug- binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers[ J] .J Biol Chem , 2001 ; 276 : 36877-80
7 Rosenberg MF , Kamis AB, Callaghan R, Higgins CF, Ford RC . Three-dimensional structures of the mammalian multidrug resis- tance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding [ J] . J Biol Chem, 2003; 278 : 8294-9
8 Martin C , Berridge G, Higgins CF, Mistry P, Charlton P, Cal- laghan R. Communication between multiple drug binding sites on P-glycoprotein[ J] . Mol Pharmacol, 2000 ; 58: 624-32
9 Garrigues A, Loiseau N , Delaforge M, Ferte J, Garrigos M, Andre F, et al .Characterization of two pharmacophores on the multi- drug transporter P-glycoprotein[ J] .Mol Pharmacol, 2002;62: 1288 -98
10 Luker GD, Flagg TP, Sha Q, Luker KE , Pica CM , Nichols CG, et al .MDR1 P-glycoprotein reduces influx of substrates without affecting membrane potential[ J] . J Biol Chem , 2001 ; 276 : 49053 -60
11 Loo TW, Bartlett MC , Clarke DM.Drug binding in human P- glycoprotein causes conformational changes in both nucleotide- binding domains[ J] .J Biol Chem, 2003; 278 : 1575 -8
12 Loo TW, Bartlett MC, Clarke DM . Cross-linking of human mul- tidrug resistance P-gly coprotein by the substrate , tris-(2-male- imidoethyl)amine , is altered by ATP hydroly sis-evidence for ro- tation of a transmembrane helix [ J] .J Biol Chem , 2001 ; 276: 31800 -5
13 Sauna ZE, Ambudkar SV.Characterization of the catalytic cy- cle of ATP hydrolysis by human P-glycoprotein-the two ATP hydroly sis events in a single catalytic cy cle are kinetically simi- lar but affect different functional outcomes[ J] .J Biol Chem, 2001 ; 276: 11653-61
14 Berridge G, Walker JA, Callaghan R, Kerr ID. The nucleotide- binding domains of P-glycoprotein-functional symmetry in the isolated domain demonstrated by N-ethylmaleimide labeling[ J] . Eur J Biochem, 2003; 270 : 1483 -92
15 Mealey KL, Barhoumi R, Burghardt RC, Safe S , Kochevar DT.Doxy cycline induces expression of P-glycoprotein in MCF-7 breast carcinoma cells [ J] .Antimicrob Agents Chemother, 2002 ; 46: 3755-61
16 Brouillard F, Tondelier D, Edelman A, Baudouin-Legros M. Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells [ J] . Cancer Res, 2001 ; 61: 1693-8
17 Kim RB.Drugs as P-glycoprotein substrates inhibitors, and in- ducers[ J] . Drug Metab Rev , 2002; 34: 47 -54
18 Yague E , Armesilla AL, Harrison G, Elliott J, Sardini A, Higgins CF, et al . P-glycoprotein (MDR1)expression in leuke- mic cells is regulated at two distinct steps, mRNA stabilization and translational initiation[ J] . J Biol Chem, 2003 ; 278: 10344 -52
19 Ding S, Chamberlain M, McLaren A, Goh L, Duncan I, Wolf CR. Cross-talk between signaling pathways and the multidrug re- sistant protein MDR-1[ J] . Br J Cancer, 2001; 85 : 1175 -84
20 Sakaeda T, Nakamura T, Hirai M, Kimura T, Wada A , Yagami T, et al .MDR1 up-regulated by apoptotic stimuli suppresses ap- optotic signaling[ J] . Pharm Res, 2002; 19 : 1323 -9
21 Cummins CL, Jacobsen W, Benet LZ .Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4[ J] .J Pharmacol Exp Ther, 2002 ; 300: 1036-45
22 Cummins CL, Salphati L, Reid MJ, Benet LZ.In vivo modu- lation of intestinal CYP3A metabolism by P-glycoprotein:studies using the rat single-pass intestinal perfusion model[ J] . J Phar- macol Exp Ther, 2003; 305: 306 -14
23 Baguley BC. Novel strategies for overcoming multidrug resistance in cancer[ J] . Biodrugs, 2002; 16 : 97-103
24 Batrakova EV, Li S , Vinogradov SV, Alakhov VY, Miller DW, Kabanov AV .Mechanism of pluronic effect on P-glycopro- 中国临床药理学与治疗学 2006 Jan; 11(1) · 19 ·tein efflux system in blood-brain barrier:contributions of energy depletion and membrane fluidization [ J] .J Pharmacol Exp Ther, 2001 ; 299: 483-93
25 Lu P, Liu R, Sharom FJ. Drug transport by reconstituted P-gly- coprotein in proteoliposomes-effect of substrates and modulators, and dependence on bilayer phase state[ J] .Eur J Biochem , 2001; 268: 1687 -97
26 Ferte J .Analysis of the tangled relationships between P-glycop- rotein-mediated multidrug resistance and the lipid phase of the cell membrane[ J] . Eur J Biochem, 2000; 267: 277 -94
27 Regev R, Assaraf YG, Eytan GD.Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycop- rotein ATPase activity and modulates efflux from multidrug-resis- tant cells[ J] .Eur J Biochem , 1999; 259: 18 -24
28 Plo I, Lehne G, Beckstrom KJ, Maestre N, Bettaieb A, Laurent G, et al . Influence of ceramide metabolism on P-glycop- rotein function in immature acute myeloid leukemia KG1a cells [ J] .Mol Pharmacol, 2002; 62 : 304 -12
29 Newman MJ, Rodarte JC , Benbatoul KD, Romano SJ, Zhang C, Krane S , et al .Discovery and characterization of OC144- 093, a novel inhibitor of P-gly coprotein-mediated multidrug re- sistance[ J] .Cancer Res, 2000; 60: 2964-72
30 Paul i - Magnus C , von Richter O, Burk O, Ziegler A, Mettang T , Eichelbaum M, et al .Characterization of the major metabo- lites of Verapamil as substrates and inhibitors of P-glycoprotein [ J] . J Pharmacol Exp Ther, 2000; 293 : 376 -82
31 Wandel C , Kim RB, Guengerich FP, Wood AJ .Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycop- rotein and CYP3A in vitro[ J] . Drug Metab Dispos, 2000 ; 28: 895 -8
32 Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S , et al .Safety and efficacy of the multidrug resistance inhibitor incel (Biricodar;VX-710)in combination with paclita- xel for advanced breast cancer refractory to paclitaxel [ J] . Clin Cancer Res, 2002; 8 : 670-8
33 Choo EF, Leake B, Wandel C , Imamura H , Wood AJ, Wilkinson GR, et al . Pharmacological inhibition of P-glycopro- tein transport enhances the distribution of HIV-1 protease inhibi- tors into brain and testes[ J] .Drug Metab Dispos, 2000 ; 28: 655 -60
34 van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Es- kens FA, Brouwer E, et al . The orally administered P-glycopro- tein inhibitor R101933 does not alter the plasma pharmacokinet- ics of docetaxel [ J] . Clinl Cancer Res, 2000 : 1365-71
35 Mistry P, Stewart AJ, Dangerfield W, Okiji S , Liddle C , Bootle D, et al .In vitro and in vivo reversal of P-glycoprotein- mediated multidrug resistance by a novel potent modulator, XR9576[ J] .Cancer Res, 2001; 61 : 749 -58
36 Ekins S , Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB , et al .Three-dimensional quantitative structure-activity re- lationships of inhibitors of P-glycoprotein [ J] .Mol Pharmacol , 2002; 61 : 964-73
37 Ekins S , Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB , et al .Application of three-dimensional quantitative struc- ture-activity relationships of P-gly coprotein inhibitors and sub- strates[ J] . Mol Pharmacol, 2002 ; 61: 974-81
38 Stouch TR, Gudmundsson O.Progress in understanding the structure-activity relationships of P-glycoprotein [ J] .Adv Drug Deliv Rev , 2002 ; 54: 315-28
39 Wang EJ, Casciano CN, Clement RP, Johnson WW.In Vitro flow cytometry method to quantitatively assess inhibitors of P- glycoprotein[ J] . Drug Metab Dispos, 2000; 28 : 522-8
40 Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH , et al . In vitro substrate identification studiesfor P-glycopro- tein-mediated transport :species difference and predictability of in vivo results[ J] .J Pharmacol Exp Ther, 2001; 296: 723 -35
41 Patel VA, Dunn MJ, Sorokin A . Regulation of MDR-1 (P-gly- coprotein)by cyclooxygenase-2[ J] . J Biol Chem, 2002 ;277: 38915 -20
42 Veau C, Faivre L, Tardivel S, Soursac M , Banide H , Lacour B , et al .Effect of inteleukin-2 on intestinal P-glycoprotein ex- pression and functionality in mice[ J] .J Pharmacol Exp Ther, 2002 ; 302: 742-50
43 Thevenod F, Friedmann JM, Katsen AD, Hauser IA.Up-regu- lation of multidrug resistance P-glycoprotein via nuclear factor-B activation protects kidney proximal tubule cells from cadmium- and reactiveoxygen species-induced apoptosis[ J] .J Biol Chem, 2000 ;275: 1887-96
44 Wartenberg M , Ling FC, Schallenberg M, Baumer AT, Petrat K, Hescheler J, et al .Down-regulation of intrinsic P-glycopro- tein expression in multicellular prostate tumor spheroids by reac- tive oxygen species[ J] .J Biol Chem , 2001 ; 276: 17420-28
45 Yang JM , Vassil AD, Hait WN. Activation of phospholipase C induces the expression of the multidrug resistance (MDR1)gene through the Raf-MAPK Pathway[ J] .Mol Pharmacol, 2001; 60: 674 -80
46 Gill PK, Gescher A, Gant TW.Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes αand θ [ J] . Eur J Biochem, 2001; 268 : 4151-7
47 Castro AF, Horton JK, Vanoye CG, Altenberg GA.Mechanism of inhibition of P-glycoprotein-mediated drug transport by protein kinase C blockers[ J] .Biochem Pharmaco , 1999; 58: 1723 -33
48 da Rocha AB, Mans DR, Regner A, Schwartsmann G. Target- ing protein kinase C : -new therapeutic opportunities against high- grade malignant gliomas[ J] ? Oncologist , 2002; 7: 17 -33
49 Jin S , Scotto KW. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacety lase is mediated by NF- Y[ J] .Mol Cell Biol, 1998 ; 18: 74377-84
50 Xu D, Ye D, Fisher M , Juliano RL. Selective inhibition of P- glycoprotein expression in multidrug resistant tumor cells by a designed transcriptional regulator[ J] . J Pharmacol Exp Ther, 2002 ; 302: 963-71
51 Vilaboa NE , Galan A, Troyano A , de Blas E, Aller P. Regula- tion of multidrug resistance 1(MDR1) P-glycoprotein gene ex- pression and activity by hea t - shock transcription factor 1(HSF1) [ J] . J Biol Chem , 2000; 275: 24970-6
52 Chan JY, Chu AC, Fung KP. Inhibition of P-glycoprotein ex- pression and reversal of drug resistance of human hepatoma HepG2 cells by multidrug resistance gene (mdr1) antisense RNA[ J] . Life Sci , 2000;67: 2117 -24
53 Astriab-Fisher A, Sergueev DS, Fisher M, Shaw BR, Juliano RL.Antisense inhibition of P-glycoprotein expression using pep- tide-oligonucleotide conjugates[ J] .Biochem Pharmaco , 2000;
60 : 83-90 · 20 · Chin J Clin Pharmacol Ther 2006 Jan; 11(1)54 Bashir I, Sikora K, Foster CS. Generation of a monoclonal anti- body to P-glycoprotein peptides using tuberculin-PPD as a carrier [ J] . Virchows Arch , 1998 , 432: 279-87
55 Brady JM, Cherrington NJ, Hartley DP, Buist SC , Li N, et al .Tissue distribution and chemical induction of multiple drug resistance genesin rats[ J] . Drug Metab Dispos, 2002 ; 30: 838-
44 56 Lo YL. Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial caco-2 cell layers and everted gut sacs of rats[ J] .Biochem Pharmacol , 2000; 60 : 1381 -90
57 Luciani F, Molinari A , Lozupone F, Calcabrini A, Lugini L, Stringaro A, et al .P-gly coprotein-actin association through ERM family proteins:a role in P-gly coprotein function in human cells of lymphoid origin[ J] .Blood , 2002; 99: 641 -8
58 Watts GS , Futscher BW, Isett R, Gleason-Guzman M , Kunkel MW, Salmon SE . cDNA microarray analysis of multiple defects in apoptosis signaling pathways [ J] . J Pharmacol Exp Ther, 2001; 299: 434 -41
59 Ruefli AA, Smyth MJ, Johnstone RW. HMBA induces activa- tion of a caspase-independent cell death pathway to overcome P- gly coprotein-mediated multidrug resistance[ J] .Blood , 2000 ; 95 : 2378-85
60 Johnstone RW, Tainton KM, Ruefli AA , Froelich CJ, Cerruti L, Jane SM, et al .P-glycoprotein does not protect cells against cytolysis induced by pore-forming proteins [ J] . J Biol Chem , 2001 ; 276: 16667-73
61 Schuetz EG, Umbenhauer DR, Yasuda K, Brimer C , Nguyen L, Relling MV , et al .Altered expression of hepatic cytochromes p450 in mice deficient in one or more mdr1 genes[ J] .Mol Pharmaco , 2000; 57: 188 -97
62 Frank MH , Denton MD, Alexander SI, Khoury SJ, Sayegh MH, Briscoe DM . Specific MDR1 P-glycoprotein blockade inhibits hu- man alloimmune T cell activation in vitro[ J] .J Immunol, 2001; 166 : 2451-9
63 Kondratov RV, Komarov PG, Becker Y, Ewenson A , Gudkov AV. Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycopro- tein[ J] . Proc Natl Acad Sci USA, 2001 ; 98: 14078-83
64 Stephens RH , O' Neill CA, Bennett J, Humphrey M, Henry B , Rowland M, et al .Resolution of P-glycoprotein and non-P- glycoprotein effects on drug permeability using intestinal tissues from mdr1a(- -)mice [ J] .Br J Pharmaco , 2002 ; 135: 2038 -46
65 Batrakova EV, Li S , Elmquist WF , Miller DW, Alakhov VY, Kabanov AV. Mechanism of sensitization of MDR cancer cells by pluronic block copolymers:Selective energy depletion[ J] .Br J Cancer, 2001;85: 1987 -97
66 Shain KH, Dalton WS.Cell adhesion is a key determinant in de novo multidrug resistance(MDR):-new targets for the pre- vention of acquired MDR[ J] .Mol Cancer Ther, 2001: 69 -78

[1]	郝潇, 赵美, 王文静, 张飞飞, 刘惠良, 党懿, 李树仁, 齐晓勇. 钠-葡萄糖共转运体2抑制剂在急性心肌梗死应用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 824-831.
[2]	王娟, 刘维英, 叶育才, 付文丽, 张莎, 李乐萍. 去甲肾上腺素再摄取抑制剂联合抗毒蕈碱剂治疗阻塞性睡眠呼吸暂停的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 714-720.
[3]	沈嘉庆, 刘毅. 酪氨酸激酶2抑制剂治疗斑块型银屑病机制与临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 323-330.
[4]	李珊, 柳熠鑫, 任菲菲, 李相晨, 张志清. 天然植物活性成分通过下调 P-糖蛋白逆转肿瘤多药耐药的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 331-340.
[5]	刘南玉, 岳红梅, 宋佩佩, 魏继芳, 魏雅倩, 谢莹莹, 王嘉琪. PDE4抑制剂作为肺纤维化的治疗靶点[J]. 中国临床药理学与治疗学, 2023, 28(3): 355-360.
[6]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[7]	张可心, 贾文静, 崔佳文, 敖路遥, 周芳, 王广基, 刘嘉莉. 第三代EGFR酪氨酸激酶抑制剂在非小细胞肺癌临床治疗中的应用及研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1016-1030.
[8]	王金伙, 高新跃, 郭建荣. COX-2抑制剂对老年骨科手术患者术后谵妄的影响及其可能的作用机制[J]. 中国临床药理学与治疗学, 2022, 27(8): 863-869.
[9]	何雪茹, 付裕豪, 荀雪姣, 崔艳军, 董占军. 尿苷二磷酸葡醛酸转移酶介导的酪氨酸激酶抑制剂药物相互作用研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 936-945.
[10]	刘南玉, 岳红梅, 宋佩佩, 魏继芳, 魏雅倩, 谢莹莹, 王嘉琪. 以αv为靶向的整合素作为肺纤维化的药物靶点[J]. 中国临床药理学与治疗学, 2022, 27(6): 709-714.
[11]	彭娟, 范琳琳, 李然宜, 李晓宇, 吕迁洲, 邹云增. 心力衰竭药物治疗的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 373-381.
[12]	王瑞杰, 王亮, 徐丹, 周淼淼, 李纪明. PCSK9抑制剂对冠心病患者血脂及炎症因子的影响[J]. 中国临床药理学与治疗学, 2022, 27(4): 409-417.
[13]	李远方, 崔兆强. 高血压合并高尿酸血症的应对之策[J]. 中国临床药理学与治疗学, 2022, 27(4): 428-432.
[14]	徐建飞, 林利. 高血压药物治疗与非药物治疗研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 433-441.
[15]	蒯铮, 张潇伊, 邹云增. 血管紧张素受体脑啡肽酶抑制剂在老年高血压中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 442-445.